Evidence map›Paper›PMID 27853642›Full record

ArticleOncoimmunology

RIG-I activation induces the release of extracellular vesicles with antitumor activity.

Juliane Daßler-Plenker, Katrin S Reiners, Jasper G van den Boorn, Hinrich P Hansen, Bastian Putschli, Sabine Barnert, Christine Schuberth-Wagner, Rolf Schubert, Thomas Tüting, Michael Hallek and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 55 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Human NK cells and cancer.Oncoimmunology · 2024
    Review
  9. Article
  10. Review
  11. Immunomodulatory role of EV-derived non-coding RNA in lung cancer.Extracellular vesicles and circulating nucleic acids · 2023
    Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications.International journal of molecular sciences · 2021
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Juliane Daßler-PlenkerInstitute of Clinical Chemistry and Clinical Pharmacology, University of Bonn , Bonn, Germany.
Katrin S ReinersClinic I for Internal Medicine, Innate immunity Group, University of Cologne , Cologne, Germany.
Jasper G van den BoornInstitute of Clinical Chemistry and Clinical Pharmacology, University of Bonn , Bonn, Germany.
Hinrich P HansenClinic I for Internal Medicine, Innate immunity Group, University of Cologne , Cologne, Germany.
Bastian PutschliInstitute of Clinical Chemistry and Clinical Pharmacology, University of Bonn , Bonn, Germany.
Sabine BarnertDepartment of Pharmaceutical Technology and Biopharmacy, Albert-Ludwigs-University , Freiburg, Germany.
Christine Schuberth-WagnerInstitute of Clinical Chemistry and Clinical Pharmacology, University of Bonn , Bonn, Germany.
Rolf SchubertDepartment of Pharmaceutical Technology and Biopharmacy, Albert-Ludwigs-University , Freiburg, Germany.
Thomas TütingDepartment of Dermatology and Allergy, University of Bonn , Bonn, Germany.
Michael HallekClinic I for Internal Medicine, Innate immunity Group, University of Cologne , Cologne, Germany.
Martin SchleeInstitute of Clinical Chemistry and Clinical Pharmacology, University of Bonn , Bonn, Germany.
Gunther HartmannInstitute of Clinical Chemistry and Clinical Pharmacology, University of Bonn , Bonn, Germany.
Elke Pogge von StrandmannClinic I for Internal Medicine, Innate immunity Group, University of Cologne, Cologne, Germany; Experimental Tumor Research, Center for Tumor Biology and Immunology, Clinic for Hematology, Oncology, and Immunology, Philipps University, Hans-Meerwein-Strasse 3, Marburg, Germany.
Christoph CochInstitute of Clinical Chemistry and Clinical Pharmacology, University of Bonn , Bonn, Germany.
University of Bonn · DEUniversity of Cologne · DEUniversity of Freiburg · DEPhilipps University of Marburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Activation of the innate immune receptor retinoic acid-inducible gene I (RIG-I) by its specific ligand 5'-triphosphate-RNA (3pRNA) triggers antitumor immunity predominantly via NK cell activation and direct apoptosis induction in tumor cells. However, how NK cells are mobilized to attack the tumor cells remains elusive. Here, we show that RIG-I activation induced the secretion of extracellular vesicles (EVs) from melanoma cells, which by themselves revealed antitumor activity

Indexed as

BAG6exosomesextracellular vesiclesmelanomaNK cellsNKp30RIG-I

Identifiers

PMID27853642
PMCPMC5087302
OpenAlexW2516115633

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.